(0.09%) 5 308.13 points
(-0.49%) 39 807 points
(0.65%) 16 795 points
(-0.64%) $79.29
(-0.51%) $2.74
(-0.90%) $2 416.60
(-2.45%) $31.63
(-1.98%) $1 042.60
(0.05%) $0.921
(0.21%) $10.72
(0.01%) $0.787
(0.02%) $90.70
Live Chart Being Loaded With Signals
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke...
Stats | |
---|---|
Dagens volum | 6 661.00 |
Gjennomsnittsvolum | 40 527.00 |
Markedsverdi | 116.17M |
EPS | $0 ( 2024-05-20 ) |
Neste inntjeningsdato | ( $-0.160 ) 2024-08-12 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -5.10 |
ATR14 | $0.0170 (0.56%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-22 | Lorianne Masuoka K. | Buy | 285 000 | Stock option (right to buy) |
2024-01-22 | Lorianne Masuoka K. | Buy | 0 | |
2024-01-02 | Semba Charles Pauling | Buy | 9 375 | Voting Common Shares, no par value per share |
2024-01-02 | Kuntz Richard | Buy | 14 285 | Voting Common Shares, no par value per share |
2024-01-02 | Pilnik Richard D. | Buy | 30 357 | Voting Common Shares, no par value per share |
INSIDER POWER |
---|
54.04 |
Last 91 transactions |
Buy: 8 059 792 | Sell: 2 870 847 |
DiaMedica Therapeutics Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
DiaMedica Therapeutics Økonomi
Annual | 2023 |
Omsetning: | $0 |
Bruttogevinst: | $-30 000.00 (0.00 %) |
EPS: | $-0.600 |
FY | 2023 |
Omsetning: | $0 |
Bruttogevinst: | $-30 000.00 (0.00 %) |
EPS: | $-0.600 |
FY | 2022 |
Omsetning: | $0 |
Bruttogevinst: | $-25 000.00 (0.00 %) |
EPS: | $-0.520 |
FY | 2021 |
Omsetning: | $0.00 |
Bruttogevinst: | $0.00 (0.00 %) |
EPS: | $-0.650 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
DiaMedica Therapeutics
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.